^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CMG1A46
i
Other names: CMG1A46, 1A46, BR110
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chimagen Biosci, GSK, Zhejiang Hisun
Drug class:
CD20 inhibitor, CD3 agonist, CD19 inhibitor
Related drugs:
27d
Phase I/II Clinical Study of 1A46 Drug Substance (clinicaltrials.gov)
P1, N=209, Recruiting, BioRay Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1
Enrollment open • Phase classification
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 expression • CD19 expression
|
CMG1A46
over1year
Clinical Study of 1A46 Drug Substance (clinicaltrials.gov)
P1/2, N=209, Not yet recruiting, Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
New P1/2 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 expression • CD19 expression
|
CMG1A46
over2years
First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=165, Recruiting, Chimagen Biosciences, Ltd | Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Jul 2022
Enrollment open • Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 expression • CD19 expression
|
CMG1A46
over2years
First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=165, Not yet recruiting, Chimagen Biosciences, Ltd
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 expression • CD19 expression
|
CMG1A46
Share via
